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Background: Over-the-counter-medication (OTC-medication) use during pregnancy can be potentially harmful for
the fetus. To successfully counsel the patient it is important to know if the patient is at risk. In this study possible
predictors for OTC-medication use were identified and a model was designed to predict OTC-medication use
during pregnancy.
Methods: We performed a post-hoc analysis on data collected for a clustered clinical trial to study a screening
strategy for Query fever. Pregnant women under supervision of a midwife were eligible for inclusion. These women
filled out questionnaires during their pregnancy and post-partum. These questionnaires were used to determine the
prevalence and to select possible predictors for OTC-medication use. These predictors were included in a prediction
model using multivariate analysis. The discrimination and calibration of the model were assessed with Receiver
Operating Characteristic analysis and the Hosmer and Lemeshow test.
Results: Of the 1348 women enrolling in the clustered clinical trial, we included 1246 women in this analysis. The
prevalence of OTC-medication use was 12.5%. The predictors for OTC-medication use in our cohort were: nulliparity,
use of prescription medication, the presence of a comorbidity, Body Mass Index between 26 and 30 kg/m2 and
General Practitioner visits. These predictors were used to design a prediction model for OTC-medication use. The
area under the Receiver Operating Characteristic-curve of the prediction model was 0.667 (95% CI 0.620-0.714
P<0.001) and the predictive probabilities ranged from 6.6% to 57.4%. The Hosmer and Lemeshow goodness-of-fit
test indicated good calibration of the model (P = 0.640).
Conclusion: It is possible to indicate women at risk for OTC-medication use during pregnancy, using five maternal
characteristics that independently contribute to the prediction model. The predictors are easy to estimate and the
model is easy to implement in daily practice.
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During pregnancy, there are some common ailments
many women experience. Over-the-counter medications
(OTC-medications) are widely used to treat these ailments.
Because of their wide use, some OTC-medications (e.g.
acetaminophen) are considered to be safe for pregnant
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distribution, and reproduction in any mediumtrials, the knowledge about the safety of OTC-medication
exposure during pregnancy is dependent on observa-
tional studies. The only OTC-medications that are
well-known to be potentially harmful are Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs). Fetal NSAID expos-
ure is associated with an increased risk of constriction of
the ductus arteriosus (DA) [1] and the risk of spontan-
eous abortion [2]. It is particularly difficult to investigate
the consequences of OTC-medication use on fetal out-
comes, because their use is not fully documented. Even
healthcare providers are not always aware of OTC-
medication use by their patient during pregnancy. In thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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most OTC-medications are discouraged to use during
pregnancy because of the lack of evidence for either safety
or fetal risk. Therefore, healthcare providers should pro-
vide personalized counseling to pregnant women about
possible negative side effects of OTC-medication on their
unborn child. In order to achieve this it is preferable to in-
dicate women that are at risk for OTC-medication use.
The study results published so far on OTC-medication
use during pregnancy are difficult to compare, because
research populations and study designs differ strongly.
For example, studies from the United States found per-
centages of women that self-medicated with OTC medi-
cation varying between 92,6% [4] and 53,6% [5].
Furthermore, drug utilization patterns vary strongly be-
tween different countries. It is therefore important to
study the prevalence and predictors of OTC-medication
use in a Dutch setting. Previous studies already investi-
gated drug use during pregnancy in the Netherlands, but
they used different study designs and did not focus on
OTC-medication [6,7]. By describing possible predictors
of OTC-medication use during pregnancy, midwifes and
obstetricians in the Netherlands can be assisted in
identifying pregnant women that are likely to use OTC-
medication. In this population ‘at-risk’, personalized coun-
seling can be given in order to mitigate medication-related
risks for the unborn child. We have implemented the pre-
dictors in a prediction model applicable in daily practice.
Methods
Setting and participants
The dataset used in this cross-sectional study was primarily
assembled for a clustered randomized controlled trial to
study a screening strategy for Query fever (Q fever) among
pregnant women. This clinical trial has been approved by
the ethics committee of the University Medical Center
Groningen [8]. Participants were recruited by midwife
centers in Q fever affected areas in the Netherlands
(southern part of the Netherlands; North Brabant). The
study population comprised pregnant women under su-
pervision of a midwife in primary healthcare. In the
Netherlands, midwifes are only allowed to supervise low-
risk, singleton pregnancies. Women were eligible for
inclusion if they were 18 years of age or older, and preg-
nant with an estimated date of delivery between June 1st
and December 31st 2010. Women returned the question-
naire by internet, by logging in to a protected website.
Women were ineligible for inclusion if they had no access
to internet/email, if they were unable to understand Dutch
or unable to give informed consent.
Data collection
We used data from two different questionnaires. The
first questionnaire was filled out in the second or thirdtrimester of pregnancy and included questions about the
current pregnancy, outcome of previous pregnancies,
lifestyle, comorbidities not related to pregnancy (e.g. car-
diac disease, lung disease), (OTC-)medication use during
pregnancy and socio-demographic characteristics. The
second questionnaire was completed by the participants
one month post-partum. With this questionnaire health
complaints and healthcare use during and one month
after pregnancy were examined. Data from both ques-
tionnaires were used to study possible predictors for
OTC-medication use during pregnancy.
We categorized all medication that is available without
a prescription from a doctor in the Netherlands as
OTC-medication. All drugs were classified according to
the Anatomical Therapeutic Chemical (ATC) classifica-
tion system of the World Health Organization [9] and
divided in subgroups based on complaints for which the
drugs were used. In case of small groups, different types
of medication were clustered in one group.
Folic acid and vitamin D are vitamins which are
advised in the Netherlands during pregnancy [10].
Therefore, women who have only used these vitamins
are categorized as non-OTC-medication users. When
prenatal vitamins were reported, we considered them as
multivitamins designed for pregnant women containing
more and/or other vitamins than folic acid and vitamin
D. Because prenatal vitamins are not actively advised by
midwifes in the Netherlands during pregnancy, we con-
sidered them as OTC-medication.
Outcome measures and predictor selection
The primary endpoint, the prevalence of OTC-medication
use, was calculated by using descriptive statistics. We evalu-
ated whether the primary endpoint could be predicted by
maternal characteristics. Therefore, a prediction model was
developed. For each candidate predictor included in this
model at least ten events were required [11]. Candidate
predictors are listed in Table 1. We only selected predictors
that were available in our dataset.
Statistics
The reported OTCmedications were divided into sub-
categories based on the complaints for which the medi-
cations were used. Dermatics, homeopathy, comforting
medication were combined into one category for statis-
tical reasons. Some characteristics (i.e. Body Mass Index
(BMI), ethnicity, education) were also divided into sub-
categories. For BMI, a distinction was made between
underweight (<19 kg/m2), ideal weight (19–25 kg/m2),
overweight (26–30 kg/m2) and obesity (>30 kg/m2).
However, for statistical reasons, we grouped under-
weight, ideal weight and obesity as one reference cat-
egory. For ethnicity, the sub-category ‘Western’ includes
women of Dutch origin and other Western origins. The
Table 1 Candidate predictors of OTC-medication use during pregnancy
Socio-demographic predictors Education level, age, ethnicity
Comorbidity predictors Use of prescription drugs, chronic illness, healthcare consumption, health complaints during pregnancy
Lifestyle predictors Smoking and alcohol use during pregnancy, Body Mass Index
Obstetric history predictors Gravidity, parity, miscarriage, prematurity, child mortality
The possible maternal characteristics which can predict OTC-medication use during pregnancy. Marital status is not included among the socio-demographic
predictors, because these data were not available.
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(e.g. African, Asian, Hindu). We divided education in a
‘low’, ‘middle’ and ‘high’ sub-category. High education
includes higher vocational education, middle education
includes intermediate vocational education and low
education includes all education levels that are lower
than intermediate vocational education. We performed
univariate analysis for the single associations using
Pearson’s Chi-square tests to calculate odds ratios (OR)
and 95% Confidence Intervals (95% CI). For all the stat-
istical analyses we excluded the missing values. After the
univariate analysis, we included the candidate predictors
in a multivariate analysis using logistic regression. We
used backward elimination to exclude non-contributable
predictors (P ≥0.05) from the prediction model. The
Hosmer and Lemeshow goodness-of-fit test was used to
measure how well the predicted probabilities by the
model correspond to the observed probabilities. Further-
more, a calibration plot of the observed and predicted
probabilities was made. Receiver Operating Characteris-
tic (ROC) analysis was used to test the discriminating
performance of our model. For the clinical daily practice
an equation to estimate the likelihood of OTC-medication
use for the individual woman was designed, using the
rounded regression coefficients of the multivariate ana-
lysis. All the analyses described above were performed
with PASW Statistics version 18.0 (SPSS inc. Chicago,
Illinois, USA).
Results
Out of 6860 women that were eligible for the Q fever
study, 1348 women responded and were included in theTable 2 Prevalence of OTC-medications used by pregnant wo
OTC-medication classification Frequency*
Dermatics, Homeopathy, Comforting medication± 24
Analgesics‡ 51
Cold & flu medication 22
Prenatal vitamins and other vitamins† 50
Gastro-intestinal tract medication 40
Total 187
The prevalence of OTC-medication use calculated for each group of OTC-medicatio
* Women that reported the use of two or more OTC-medications are included two
† Users of only Folic acid and/or vitamin D are excluded.
± Comforting medication includes medication for sleep disorders.
‡Analgetics includes NSAID’s and acetaminophen.prior dataset [8]. Participants that had not completed
the first questionnaire during pregnancy and participants
that did not fill out the question concerning OTC-
medication use were excluded from all the analyses.
1246 participants were eligible for final inclusion in the
analysis. Of these women, 157 women (12.5%) reported
OTC-medication use during pregnancy, with an average
of 1.19 OTC-medications per woman. The most com-
monly reported medications were analgesics, (prenatal)
vitamins and medication for the gastro-intestinal tract
(Table 2).
The baseline characteristics and the results of the
univariate analyses of the predictors in relation to overall
OTC-medication use during pregnancy are shown in
Table 3. Women were more likely to use OTC-medication
if they: used prescription drugs (OR 2.36 95% CI
1.54-3.62), were nulliparous (OR 1.66 95% CI 1.13-
2.33), had their first pregnancy (OR 1.57 95% CI
1.13-2.01), had a BMI between 26–30 kg/m2 (OR
1.49 95% CI 1.00-2.21), had health complaints during
pregnancy (OR 2.19 95% CI 1.55-3.10), reported
more GP visits during pregnancy (2 times: OR 1.74
95% CI 1,04-2.93 and ≥ 3 times OR 2.34 95% CI 1.30-
4.22), reported extra visits to the midwife (1 time extra:
OR 1.70 95% CI 1.05-2.73 2 times extra: OR 2.10 95% CI
1.12-3.91) and if they had a comorbidity (OR 2.37 95%
CI 1.90-4.35).
The next step was a multivariate analysis including
predictors selected from the univariate analysis and
known from literature [4,5,12-14]. Because data were
missing for some variables 89 women were excluded for
the multivariate analysis; 1157 women were included.men








times or more in this prevalence calculation.
Table 3 Baseline characteristics and results of univariate analyses of the predictors in relation to OTC-medication use
Predctor N OTC-medication use (n) % No OTC-medication use (n) % df P (Chi2) OR (95% CI)
Prescription drugs
Yes 148 34 23.0 114 77.0 1 0.000 2.36 (1.54-3.62)
No 1097 123 11.2 974 88.8
Age
18-35 1080 132 12.2 948 87.8 1 0.305
>35 166 25 15.1 141 84.9 1.27 (0.80-2.02)
Ethnicity
Western 1217 150 12.3 1067 87.7 1 0.102
Non-western 26 6 23.1 20 79.9 2.13 (0.84-5.40)
Nulliparity
Yes 561 88 15.7 473 84.3 0.003 1.66 (1.19-2.33)
No 685 69 10.1 616 89.9 1
Gravidity
1 482 76 15.8 406 84.2 1 0.007 1.57 (1.13-2.01)
2 or more 764 81 10.6 683 89.4
Parity≠
0 561 88 15.7 473 84.3 3 0.028 1.84 (1.06-3.18)
1 500 52 10.4 448 89.6 1.15 (0.65-2.04)
2 or more 185 17 9.2 168 90.8
Adverse obstetric outcome in history*
No 946 124 13.1 822 86.9 1 0.338 1.22 (0.81-1.84)
Yes 300 33 11.0 267 89.0
Miscarriage
Yes 270 29 10.7 241 89.3 1 0.298
No 976 128 13.1 848 86.9 1.25 (0.82-1.92)
Prematurity/mortality
No 1200 150 12.5 1050 87.5 1 0.586
Yes 46 7 15.2 39 84.8 1.26 (0.55-2.86)
Educationτ
Low 88 7 8.0 81 92.0 2 0.377
Middle 412 55 13.3 357 86.7 1.78 (0.78-4.06)
High 744 95 12.8 649 87.2 1.69 (0.76-3.78)
Body Mass Index(kg/m2)Ξ
<26 >30 1013 119 11.70 894 88.30 1 0.049
26-30 230 38 16.5 192 83.5 1.49 (1.00-2.21)
Smoking during pregnancy
No 1129 145 12.8 984 87.2 1 0.422 1.29 (0.69-2.40)
Yes 117 12 10.3 105 89.7
Alcohol consumption during pregnancy
No 1216 151 12.4 1065 87.6 1 0.185
Yes 29 6 20.7 23 79.3 1.84 (0.74-4.59)
Health complaints
No 779 74 9.5 705 90.5 1 0.000
Yes 401 75 18.7 326 81.3 2.19 (1.55-3.10)
General Practitioner visits±
0 695 74 10,6 621 89,4 3 0,013
1 260 34 13,1 226 86,9 1.26 (0.82-1.95)
Verstappen et al. BMC Public Health 2013, 13:185 Page 4 of 9
http://www.biomedcentral.com/1471-2458/13/185
Table 3 Baseline characteristics and results of univariate analyses of the predictors in relation to OTC-medication use
(Continued)
2 128 22 17.2 106 82.8 1.74 (1.04-2.93)
3 or more 78 17 21.8 61 78.2 2.34 (1.30-4.22)
Extra midwife visits†
0 929 104 11.2 825 88.8 3 0.028
1 142 25 17.6 117 82.4 1.70 (1.05-2.73)
2 67 14 20.9 53 79.1 2.10 (1.12-3.91)
3 or more 51 7 13.7 44 86.3 1.26 (0.55-2.88)
Other healthcare providers
0 1067 131 12.3 936 87.7 3 0.274
1 23 2 8.7 21 91.3 0.68 (0.16-2.94)
2 15 1 6.7 14 93.3 0.51 (0.07-3.91)
3 or more 85 16 18.8 69 81.2 1.66 (0.93-2.94)
Comorbidity‡
No 1099 119 10.8 980 89.2 1 0.000
Yes 147 38 25.9 109 74.1 2.87 (1.90-4.35)
n = number of women in the group.
The reference categories are dichotomous.
* Adverse obstetric outcome in history includes all cases of miscarriage, prematurity and mortality of the child in the obstetric history.
† Extra midwife visits are visits beside the regular consults by the midwife. No extra midwife visits is the reference category.
‡ Comorbidity includes any kind of comorbidity (e.g. cardiac disease, lung disease and other chronic diseases) reported by the pregnant women. These
comorbidities exclude pregnancy complications.
± No extra GP visits is the reference category.
≠ Never gave birth (parity = 0) is the reference category.
T Low-education level is the reference category.
Ξ BMI is pre-pregnancy BMI.
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with the multivariate analysis includes only the variables
that independently predict OTC use. These variables are:
Prescription drug use, nulliparity, comorbidity, BMI 26–
30 kg/m2 and the number of GP visits during pregnancy
(1, 2, 3 or more than 3 times).
The discrimination ability of the model was indicated
by an area under the ROC-curve (Figure 1) of 0.667
(95% CI 0.620-0.714 P<0.001). For the individuals the
predicted probability ranged from 6.6% to 57.4%. For the
two highest groups of the predictive probabilities thereTable 4 Results of the multivariate analysis of the predictors




Body Mass Index (kg/m2) ≠ 0.483
1 General Practitioner visit Τ 0.224
2 General Practitioner visits Τ 0.507
≥3 General Practitioner visits Τ 0.684
*Odds Ratio and the 95% confidential intervals.
† No use of prescription drugs is the reference category.
‡ Never been pregnant (nulliparity) is the reference category.
± No comorbidities is the reference category.
≠A BMI of <26 >30 kg/m2 is the reference category.
Τ No extra visits to the GP is the reference category.is a small under- and overestimation of OTC-medication
use (Figure 2). The P-value of 0.640 produced by the
Hosmer and Lemeshow goodness-of-fit test supports
that the model statistically fitted (P>0.05). For the clin-
ical daily practice an equation to calculate individual risk
scores was designed (Equation 1). This score is an indi-
cation for the probability that a pregnant woman will
use OTC-medication. The maximum score is 13, indicat-
ing the highest chance of OTC-medication use, and the
minimum score is 0, indicating the lowest chance of
OTC-medication use.in relation to OTC-medication use during pregnancy








Figure 1 ROC-curve of the multivariate analyses. ROC-curve =
Receiver-operating characteristic. AUC = area under the curve. 95%
CI = 95% confidential interval.
Figure 2 Calibration plot of the predicted probability (deciles)
versus the observed probability. * Decile 1 till 3 were taken
together since the predicted probabilities were equal.
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medication use during pregnancy
Risk score ¼ 2  prescription drugþ 2
 nulliparity þ 4  comorbidity þ 2
 BMIþ number of visits GP
Prescription drug:
fill out 1 if any kind of prescription drug is used.
Nulliparity:
fill out 1 if the woman is nulliparous.
Comorbidity:
fill out 1 if any kind of comorbidity is reported.
BMI:
fill out 1 if BMI is between 26 and 30 kg/m2.
Number of visits GP:
fill out the number of visits to the GP in the last
10 months. If the woman visited the GP more
than three times, fill out 3.
The scores and the predictive probabilities are shown
in Table 5. This table can be used by a healthcare pro-
vider for decision making during a consult. The mean
predictive probability is 0.066 by a score of 0 and 0.574
by a score of 13.
Discussion
We found that the prevalence of OTC-medication use in
a Dutch cohort of pregnant women was 12.5%. Five
predictors including nulliparity, prescription drug use,comorbidity, BMI and GP visits could be identified and
these predictors were used to design a prediction model
which is easy to implement in clinical practice. The
prediction model assists healthcare professionals in
identifying pregnant women that are likely to use OTC-
medication, so information can be given directly to the
women at risk.
Although it is difficult to compare because of the di-
vergence in study designs and study populations, the
prevalence of 12.5% is low in comparison to similar
studies that have been published [4,5,12,13]. An Irish
study found a prevalence of 19.5% [13] (2010) and stud-
ies from the United States found percentages of women
that self-medicated with OTC-medication varying be-
tween 92,6% [4] (2003) and 53,6% [5] (1993). A recent
study among Hispanic women from the United States
found a prevalence of 23% [15] (2010). A Dutch study
which was published in 1991 found a prevalence of 45%
[16]. Because these data were collected 21 years ago, the
population is not representative for the population now-
adays. It is likely that pregnant women today are more
aware of the risks of medication use during pregnancy
and this could explain the low prevalence of OTC-
medication use in our study. Another explanation for
the large difference in prevalence between our study and
the study from 1991 is that de Jong-van den Berg et al.
assembled data by an interview of approximately 30 mi-
nutes and medication use was ascertained in detail in
three different ways. Besides that, all vitamins -except
folic acid- were included in their study whereas we
excluded vitamin D users. Other studies on drug use
during pregnancy performed in the Dutch population
are not comparable to our study, because they used data
collected from the pharmacy information system or
Table 5 Scores, predictive probabilities and the percentage of women in each category
Score Mean predictive
probability
Sensitivity Specificity Number of persons Number of persons (%) Cumulative percent number
of persons
13 0.574 1 0.1 100.0
12 - - - -
11 0.456 1 0.1 99.9
10 0.411 0.027 0.989 13 1.1 99.8
9 0.349 0.082 0.974 23 2.0 98.7
8 0.301 0.122 0.956 24 2.1 96.7
7 0.258 0.170 0.939 25 2.2 94.6
6 0.217 0.286 0.897 59 5.1 92.5
5 0.182 0.374 0.841 70 6.1 87.4
4 0.155 0.497 0.740 120 10.4 81.3
3 0.124 0.599 0.634 122 10.5 71.0
2 0.102 0.857 0.342 333 28.8 60.4
1 0.081 0.912 0.256 94 8.1 31.6
0 0.066 272 23.5 23.5
The score is the outcome of the risk score formula:
Risk score = 2 x prescription drug + 2 x nulliparity + 4 x comorbidity + 2 x BMI + number of visits GP.
Prescription drug: fill out 1 if any kind of prescription drug is used.
Nulliparity: fill out 1 if the woman is nulliparous.
Comorbidity: fill out 1 if any kind of comorbidity is reported.
BMI: fill out 1 if BMI is between 26 and 30 kg/m2.
Number of visits GP: fill out the number of visits to the GP in the last 10 months. If the woman visited the GP more than three times, fill out 3.
The mean predictive probability is the chance that a women with that score uses OTC-medication. The number of persons are the number of persons in our
database having a particular score.
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administered drugs [6,7].
Previous studies described that the use of OTC-
medication was positively related to multiple illnesses
[4,5], Caucasians [4,5,12], women with more than a high
school education [12], women who were at least 20 years
of age [12,13], nulliparity [13], smoking [13,14] and be-
ing single [13]. We included all these variables in our
study, except for marital status, because those data were
not available. Besides the five predictors previously men-
tioned, we also found a non-significant higher frequency
of OTC-medication use in non-Western women com-
pared to Western women. Non-Western women were
underrepresented (n = 26) in the study due to the exclu-
sion criteria. Therefore, the predictor was not strong
enough to include in the multivariate model. We en-
countered the same power problem for the association
between OTC-medication use and the variables alcohol
use (n=6), previous prematurity/child mortality (n = 7)
and low education (n=7). Therefore, the study results
should be interpreted with caution for women with (one
of ) these characteristics.
Although our results partially differ from the predic-
tors published so far, we were able to design a strong
prediction model, with five predictors that independently
contribute. Further research with larger cohorts is neces-
sary to study the non-significant associations. The score
(Table 5) and the equation (Equation 1) are designed foruse in daily practice. Women with a score of 8 or higher
have 30.1%-57.4% chance of using OTC-medication dur-
ing pregnancy. 5.4% of the women included fell into this
category. 63% of the women had a score between 2 and
7 and 31.6% of the women had a score between 0 and 1.
Explorative analysis showed that the rule performed
more or less similar results for subgroups of medica-
tions. We suggest the women with a score of 8 or higher,
are eligible for comprehensive information provision.
The sensitivity and specificity of the model at this cut-
off score are 0.122 and 0.956, respectively. This means
that the chance of a false positive result is small, while
the chance of a false negative result is large. Sensitivities
and specificities of the model at other cut-off values
are represented in Table 5. The choice of a cut-off
score is arbitrary and healthcare providers should make
their own considerations concerning the information
provision to pregnant women that are at risk for OTC-
medication use.
Our study is the first in identifying predictors of OTC-
medication use in the Dutch population. Other strong
points of our study are the large cohort size (n=1246)
and the completeness of the data concerning a variety of
socio-demographic, obstetric and medical characteristics.
Because our dataset was primarily assembled for a study
with another objective and because the questionnaire
was filled out prior to delivery, the reporting of OTC-
medication use was relatively unbiased. Another strong
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reporting. This reflects the reporting of (OTC-)medica-
tion use in daily practice.
A limitation of this study is that, for the analyses,
OTC-medication use was coded as present or absent
and not subdivided per medication group. Explorative
analyses of the predictors per subgroup of OTC-
medication (e.g. analgesics, vitamins or medication for
gastro-intestinal tract) showed that the predictors for
each subgroup were comparable to the predictors of
overall OTC-medication use (data available on request).
However, a larger cohort is necessary to examine the
strength of the associations per subgroup.
Another limitation of our study is that the prevalence
of OTC-medication use may have been underestimated.
The questionnaires have been filled out in different
stages of pregnancy, with a range from 13 to 40 weeks.
Especially self-reporting of (OTC-)medication later in
pregnancy can lead to under-reporting due to poor re-
call. When a questionnaire is completed earlier in preg-
nancy the medication use afterwards is not known.
Another potential cause of under-reporting is the ques-
tionnaire design, because an open-ended question was
used to gain information about OTC-medication use. It
has been reported that questions involving indication for
use and drug-specific questions increase the prevalence
estimates compared to open-ended questions. However,
healthcare professionals commonly use open-ended
questions. Therefore, we think that our data reflect the
reporting in daily practice, while the actual use might be
under-estimated. Healthcare professionals should take
the questionnaire design into account while interpreting
the results of this study. A third limitation is that
the population is not representative for secondary
healthcare. We assume that the predictors we have se-
lected are still relevant in secondary healthcare, but
other risk factors may contribute as well. Finally, the
participants reported the number of GP visits during
pregnancy one-month post-partum. This contradicts
with the terms that only predictors that are available
at the time the model will be used should be in-
cluded in the prediction model [11]. Nevertheless we
have decided to include this post-partum variable,
because it is likely that there is an association be-
tween OTC-medication use during pregnancy and
the number of GP visits. This association may exist,
because pregnant women who visit their GP are
more likely to suffer from pregnancy ailments and
may use OTC-medication consequently.
A fourth limitation of our study is that the model
was not internally validated. Therefore, we may have
overestimated the predictive value of the model. Fur-
ther research is recommended to validate the model
and avoid the risk of overestimation.Conclusion
Finally, we included five predictors in our model
(nulliparity, prescription drug use, comorbidity, BMI26-
30 kg/m2 and GP visits) and found an area under the
ROC-curve of 0.667. This value suggests that our model
is moderately discriminating. On the other hand, the
variability in predicted probabilities ranged from 6.6% to
57.4% and this indicates that the model is well discrim-
inative. The Hosmer and Lemeshow test validated that
the model is statistically fitted (P= 0.640).
To optimize the prediction model there is a need for
studies with larger cohorts and studies that ascertain
(OTC-)medication use more in detail. However, our
study outcome gives a good indication of maternal char-
acteristics that are positively associated with OTC-
medication use and provides a risk score that is easy to
implement in clinical practice.
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